FDA
-
-
-
-
-
-
-
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
-
-
-
-
-
-
-
Tarsus Pharmaceuticals adds former Allergan CEO David Pyott to board
-
-
-
-
-
-
-
Tarsus to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Elanco Animal Health (ELAN) sells certain royalties and commercial milestones associated with XDEMVY to Blackstone Life Sciences and Blackstone Credit & Insurance for $295M Cash
-
-
-
-
-
-
-
Tarsus Pharmaceuticals (TARS) Announces Proposed $100M Public Offering
-
-
-
-
-
-
-
Tarsus Pharmaceuticals (TARS) Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
-
-
-
-
-
-
-
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
-
322,937 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

